RA CAPITAL MANAGEMENT, L.P. - 17 Nov 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
ACRV
Transactions as of
17 Nov 2022
Net transactions value
+$42,368,750
Form type
4
Filing time
21 Nov 2022, 15:31:14 UTC
Previous filing
16 Nov 2022
Next filing
05 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Conversion of derivative security +994,706 994,706 17 Nov 2022 See Footnotes F1, F2, F4
transaction ACRV Common Stock Purchase $42,368,750 +3,389,500 +341% $12.50 4,384,206 17 Nov 2022 See Footnotes F2, F4
transaction ACRV Common Stock Conversion of derivative security +426,302 426,302 17 Nov 2022 See Footnotes F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Series B Preferred Stock Conversion of derivative security $0 -2,452,947 -100% $0.000000* 0 17 Nov 2022 Common Stock 994,706 See footnotes F1, F2, F4
transaction ACRV Series B Preferred Stock Conversion of derivative security $0 -1,051,263 -100% $0.000000* 0 17 Nov 2022 Common Stock 426,302 See footnotes F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date.
F2 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.